PE22898A1 - Formulaciones farmaceuticas - Google Patents

Formulaciones farmaceuticas

Info

Publication number
PE22898A1
PE22898A1 PE1996000831A PE00083196A PE22898A1 PE 22898 A1 PE22898 A1 PE 22898A1 PE 1996000831 A PE1996000831 A PE 1996000831A PE 00083196 A PE00083196 A PE 00083196A PE 22898 A1 PE22898 A1 PE 22898A1
Authority
PE
Peru
Prior art keywords
weight
replacement
degree
pharmaceutical formulations
solubility
Prior art date
Application number
PE1996000831A
Other languages
English (en)
Inventor
Ross James Macrae
Janet Sarah Smith
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of PE22898A1 publication Critical patent/PE22898A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

CARACTERIZADAS PORQUE COMPRENDEN: A) HASTA UN 50% EN PESO DE UN FARMACO ACTIVO QUE PRESENTA CUALQUIERA DE LAS TRES CARACTERISTICAS SIGUIENTES: i) ALTA SOLUBILIDAD, ii) BAJA SOLUBILIDAD, iii) DEBIL BASICIDAD, TAL COMO LA DOXAZOSINA; B) DE 5% A 30% EN PESO DE POLI(OXIDO DE ETILENO) DE BAJO PESO MOLECULAR, PREFERENTEMENTE ENTRE 100 000 A 300 000; C) DE 10% A 60% EN PESO DE HIDROXIPROPILMETILCELULOSA, EN DONDE: DE 19% A 30% ES EL GRADO DE SUSTITUCION DEL METILO Y DE 4% A 12% ES EL GRADO DE SUSTITUCION DEL HIDROXILO; D) DE 10% A 40% EN PESO DEL POLIMERO ENTERICO TAL COMO EL COPOLIMERO DE ACIDO METACRILICO; E) DE 5% A 10% EN PESO DE RECUBRIMIENTO ENTERICO. ESTAS FORMULACIONES PERMITEN QUE LA EROSION DE LA MATRIZ SE CONSIGA DESPUES DE UN PERIODO PREDETERMINADO DE TIEMPO, 6 HORAS, CONTADO DESPUES DE LA ADMINISTRACION DE LA FORMULACION, LOGRANDO UNA VELOCIDAD CONSTANTE DE LIBERACION DEL FARMACO EN EL TRACTO GASTROINTESTINAL DEL PACIENTE
PE1996000831A 1995-11-21 1996-11-20 Formulaciones farmaceuticas PE22898A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9523752.5A GB9523752D0 (en) 1995-11-21 1995-11-21 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
PE22898A1 true PE22898A1 (es) 1998-05-07

Family

ID=10784188

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000831A PE22898A1 (es) 1995-11-21 1996-11-20 Formulaciones farmaceuticas

Country Status (29)

Country Link
EP (1) EP0862437A1 (es)
JP (1) JPH10513481A (es)
KR (1) KR19990071505A (es)
CN (1) CN1215993A (es)
AP (1) AP718A (es)
AR (1) AR004335A1 (es)
AU (1) AU709560B2 (es)
BG (1) BG102438A (es)
BR (1) BR9611626A (es)
CA (1) CA2232715A1 (es)
CO (1) CO4480020A1 (es)
CZ (1) CZ155498A3 (es)
GB (1) GB9523752D0 (es)
HR (1) HRP960554A2 (es)
HU (1) HUP9903734A3 (es)
IS (1) IS4706A (es)
MA (1) MA26410A1 (es)
MX (1) MX9804008A (es)
NO (1) NO982302L (es)
NZ (1) NZ322053A (es)
OA (1) OA10687A (es)
PE (1) PE22898A1 (es)
PL (1) PL326981A1 (es)
SK (1) SK63098A3 (es)
TN (1) TNSN96141A1 (es)
TR (1) TR199800902T2 (es)
WO (1) WO1997018814A1 (es)
YU (1) YU62096A (es)
ZA (1) ZA969722B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0100705A3 (en) * 1997-12-16 2001-12-28 Pfizer Prod Inc Combination effective for the treatment of impotence
AU736951C (en) 1998-03-19 2003-02-20 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
EP0974343B1 (en) * 1998-07-22 2004-09-29 Pharma Pass II LLC Process for manufacturing a solid metoprolol composition
EP0987020A1 (en) * 1998-09-04 2000-03-22 Pharma Pass LLC Metoprolol composition and processes for manufacturing the same
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US20030059467A1 (en) * 2001-09-14 2003-03-27 Pawan Seth Pharmaceutical composition comprising doxasozin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005037247A2 (en) * 2003-10-17 2005-04-28 Ranbaxy Laboratories Limited Oral matrix formulations of doxazosin
US20050255157A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Sustained release, mucoadhesive vaginal pharmaceutical compositions
KR100574554B1 (ko) * 2004-05-28 2006-04-27 한미약품 주식회사 니아신의 경구투여용 서방성 조성물
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
KR100679111B1 (ko) * 2004-11-20 2007-02-07 대우약품공업주식회사 독사조신을 포함하는 서방성 정제
MX2008002492A (es) * 2005-08-22 2008-04-03 Novartis Ag Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante.
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP2359830B1 (en) 2006-04-26 2012-09-19 Supernus Pharmaceuticals, Inc. Controlled released preparations of oxcarbazepine having sigmoidal release profile
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
NO347644B1 (no) 2006-05-04 2024-02-12 Boehringer Ingelheim Int Polymorfer
CN100396282C (zh) * 2006-07-25 2008-06-25 山东省医药工业研究所 甲磺酸多沙唑嗪缓释胶囊及制备方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
EP2262484B1 (en) 2008-03-11 2013-01-23 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
CN104906582A (zh) 2009-02-13 2015-09-16 勃林格殷格翰国际有限公司 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
EA201101524A1 (ru) 2009-04-20 2012-07-30 Элселикс Терапьютикс, Инк. Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
JP6042330B2 (ja) 2010-07-09 2016-12-14 ビーエイチヴィ ファーマ、インコーポレイテッド レモグリフロジンを含めた半減期が短い医薬品のための組合せ即時／遅延放出送達システム
AU2011317140A1 (en) 2010-10-19 2013-05-30 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
SG10201607085WA (en) 2011-01-07 2016-10-28 Elcelyx Therapeutics Inc Chemosensory Receptor Ligand-Based Therapies
CN102058555A (zh) * 2011-01-13 2011-05-18 北京汇诚瑞祥医药技术有限公司 一种多沙唑嗪控释片
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
CN102188431A (zh) * 2011-05-09 2011-09-21 浙江九旭药业有限公司 甲磺酸多沙唑嗪缓释片及其制备方法
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP2016520653A (ja) 2013-06-05 2016-07-14 シンクロニューロン インコーポレイテッド アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
CN105616378A (zh) * 2014-10-31 2016-06-01 康普药业股份有限公司 一种氟康唑胶囊及其制备方法
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1198386B (it) * 1982-07-06 1988-12-21 Lepetit Spa Un prodotto a rilascio protratto contenente il suloctidile
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
PT98374A (pt) * 1990-07-23 1994-01-31 Alza Corp Dispositivo osmotico para administracao sistemica de nicotina e processo nele baseado

Also Published As

Publication number Publication date
GB9523752D0 (en) 1996-01-24
EP0862437A1 (en) 1998-09-09
TNSN96141A1 (fr) 2005-03-15
HRP960554A2 (en) 1998-02-28
HUP9903734A2 (hu) 2000-03-28
HUP9903734A3 (en) 2000-04-28
MX9804008A (es) 1998-09-30
YU62096A (sh) 1999-03-04
WO1997018814A1 (en) 1997-05-29
BR9611626A (pt) 1999-06-01
AP9600883A0 (en) 1997-01-31
AR004335A1 (es) 1998-11-04
CZ155498A3 (cs) 1999-03-17
CA2232715A1 (en) 1997-05-29
SK63098A3 (en) 1999-05-07
BG102438A (en) 1999-01-29
NO982302D0 (no) 1998-05-20
NZ322053A (en) 1999-11-29
AU7572196A (en) 1997-06-11
AU709560B2 (en) 1999-09-02
CN1215993A (zh) 1999-05-05
OA10687A (en) 2002-11-27
ZA969722B (en) 1998-05-20
JPH10513481A (ja) 1998-12-22
IS4706A (is) 1998-03-31
MA26410A1 (fr) 2004-12-20
KR19990071505A (ko) 1999-09-27
CO4480020A1 (es) 1997-07-09
PL326981A1 (en) 1998-11-09
TR199800902T2 (xx) 1998-09-21
NO982302L (no) 1998-07-17
AP718A (en) 1999-01-06

Similar Documents

Publication Publication Date Title
PE22898A1 (es) Formulaciones farmaceuticas
ES2349924T3 (es) Composición de polisacáridos reticulados.
US7943596B2 (en) Medicinal composition for ophthal use containing acetylated hyaluronic acid
ES2531679T3 (es) Composiciones para la administración de liberación controlada de péptidos
DE69414840D1 (de) Akzeptabele pharmazeutische zusammensetzung enthaltend einen alkohol und einen hydrophalischen wirkstoff
US8834927B2 (en) Thermogelling anaesthetic compositions
PE20040675A1 (es) Formulaciones de deposito de liberacion controlada
MX2014015902A (es) Suministro de farmaco biodegradable para las composiciones hidrofobicas.
US10582915B2 (en) Film for oral hemostasis and wound protection
ATE468848T1 (de) In organischen lösemitteln lösliche biologisch abbaubare poly (alkylenoxid)- poly (p-dioxanon) blockcopolymere sowie diese enthaltende zusammensetzung zur arzneistoffverabreichung
CA2458853A1 (en) Use of fucans in the treatment of adhesions, arthritis and psoriasis
CA2430481A1 (en) Compositions for sustained delivery of hydrophobic drugs and process for the preparation thereof
KR101066763B1 (ko) 온도 반응성 전달계
AR003427A1 (es) Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas.
AR065073A2 (es) Una formulacion medicamentosa de sistema de matriz que tiene liberacion controlada de un compuesto activo
CN101415442A (zh) 控释凝胶
TW200519129A (en) Biodegradable hyaluronic acid derivative, biodegradable polymeric micelle composition, and pharmaceutical or bioactive composition containing the micelle composition
US9345779B2 (en) Aqueous ophthalmic composition
TR200101088T2 (tr) Sürekli salınımlı farmasötik kompozisyon ve farmasötik olarak aktif ajanın salınma metodu
ES2399166T3 (es) Formulaciones tópicas antivíricas en la forma de un gel bio-adhesivo
FI923385A0 (fi) Foerfarande foer framstaellning av en oral farmaceutisk sammansaettning som innehaoller cyklosporin.
CA2466657A1 (en) Soluble drug extended release system
JPH0859512A (ja) フィルムコーティング組成物およびそれを用いた固形製剤
CN103211755A (zh) 无菌稳定的阿奇霉素滴眼液的生产方法
Kovalenko et al. Metodological aspects of development of gels for treating inflammatory dental diseases

Legal Events

Date Code Title Description
FC Refusal